Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01129687 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 25, 2010
Last Update Posted : September 11, 2018
|
Sponsor:
Stanford University
Collaborators:
University of Cincinnati
Baylor College of Medicine
Weill Medical College of Cornell University
University of Iowa
University of Texas
George Washington University
Indiana University
Louisiana State University Health Sciences Center in New Orleans
Information provided by (Responsible Party):
Ashkan Monfared, George Washington University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The investigators study is to investigate safety and efficacy of performing a planned incomplete removal of large acoustic neuroma tumors to decrease surgical morbidity and yet avoid tumor recurrence by post-operative radiation therapy.
| Condition or disease | Intervention/treatment |
|---|---|
| Neuroma, Acoustic | Procedure: Microsurgery Procedure: Stereotactic radiation therapy |
The current standard treatment of a large tumor of the balance nerve (acoustic neuroma or vestibular schwannoma) is surgical resection. Complete removal of such tumor is associated with significant risks of hearing loss and facial paralysis whereas incomplete removal of the tumor is associated with significant risks of regrowth. Stereotactic radiation is a well accepted therapy aiming at stopping the growth of smaller acoustic neuromas before their sizes become large enough to cause problems. The purpose of our study is to determine whether the combination of subtotal resection followed by stereotactic radiation of the remnant can control large acoustic neuromas without the significant risks associated with complete resection.
| Study Type : | Observational |
| Estimated Enrollment : | 200 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Multicenter Prospective Analysis of Treatment Outcome in Patients With Large Acoustic Neuromas |
| Study Start Date : | March 2005 |
| Estimated Primary Completion Date : | March 2025 |
| Estimated Study Completion Date : | March 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Acoustic Neuroma
| Group/Cohort | Intervention/treatment |
|---|---|
|
ANSRS group
Patients qualifying for the study.
|
Procedure: Microsurgery
Patient would under to total, near-total, or subtotal resection of tumor Procedure: Stereotactic radiation therapy Patient who has sign of growth of tumor remnant would undergo this treatment |
Primary Outcome Measures :
- Need for stereotactic radiation therapy should tumor remnant grow on annual MRI's [ Time Frame: 10 years ]
Secondary Outcome Measures :
- Facial nerve function measured on House-Brackmann scale [ Time Frame: 10 y ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with large acoustic neuromas measuring 2.5cm in longest dimension in the cerebellopontine angle.
Criteria
Inclusion Criteria:
- Adult patients with acoustic neuromas the widest diameter of 2.5 cm or larger at the cerebellopontine angle are eligible for this trial.
- Patients that are deemed good surgical candidates based on age, general health, genetic predispositions, and hearing in contralateral side would be included as the subjects of this trial.
- Although we would include patients with neurofibromatosis II in this trial, considering their genetic predisposition for recurrence, we would analyze their outcome as a separate group.
Exclusion Criteria:
- Patients who have received any form of treatment of their acoustic neuromas prior to enrollment in the study including surgery or radiation therapy.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01129687
Locations
| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
| United States, District of Columbia | |
| George Washington University | |
| Washington, District of Columbia, United States, 20037 | |
| United States, Indiana | |
| Indiana University | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Iowa | |
| University of Iowa | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Louisiana | |
| Louisiana State University | |
| Baton Rouge, Louisiana, United States, 70808 | |
| United States, New York | |
| Weill Cornell Medical College | |
| New York, New York, United States | |
| United States, Ohio | |
| University of Cincinnati | |
| Cincinnati, Ohio, United States | |
| United States, Texas | |
| University of Texas Southwestern | |
| Dallas, Texas, United States, 75390 | |
| Baylor College of Medicine | |
| Houston, Texas, United States | |
Sponsors and Collaborators
Stanford University
University of Cincinnati
Baylor College of Medicine
Weill Medical College of Cornell University
University of Iowa
University of Texas
George Washington University
Indiana University
Louisiana State University Health Sciences Center in New Orleans
Investigators
| Study Director: | Ashkan Monfared, MD | George Washington University | |
| Study Director: | Robert K Jackler, MD | Stanford University |
| Responsible Party: | Ashkan Monfared, Principal Investigator, George Washington University |
| ClinicalTrials.gov Identifier: | NCT01129687 History of Changes |
| Other Study ID Numbers: |
SU-03052010-5142 |
| First Posted: | May 25, 2010 Key Record Dates |
| Last Update Posted: | September 11, 2018 |
| Last Verified: | September 2018 |
Additional relevant MeSH terms:
|
Neuroma Neuroma, Acoustic Nerve Sheath Neoplasms Neoplasms, Nerve Tissue Neoplasms by Histologic Type Neoplasms Neurilemmoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Cranial Nerve Neoplasms |
Nervous System Neoplasms Neoplasms by Site Peripheral Nervous System Neoplasms Vestibulocochlear Nerve Diseases Retrocochlear Diseases Ear Diseases Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Cranial Nerve Diseases Nervous System Diseases |